Bristol-Myers Squibb data supporting Questran switch found lacking by FDA committee.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS' QUESTRAN Rx-TO-OTC SWITCH DATA FOUND INSUFFICIENT to support the over-the-counter availability of the product by FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees at a joint meeting on Sept. 27. Bristol-Myers Squibb is seeking FDA approval to market Questran (cholestyramine) and Questran Light as OTC treatments for hypercholesterolemia.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning